Share

Market insight in association with

Illegal online pharmacies: how endemic are they?

Illegal pharmacies are defined as those that operate without certification, prescribe drugs without adhering to legal guidelines, or knowingly distribute counterfeit medicines. In recent years, increased interest in e-commerce and the anonymity offered by the internet has led to illegal online pharmacies taking hold. According to The Alliance for Safe Online Pharmacies (ASOP) 100% of online searches for the phrase “buy medicine online” return links for illegal online pharmacies.  A report from The Centre for Safe Internet Pharmacies claims that each month, 600 new illegal online pharmacies are launched; taking advantage of this ever-increasing market that has generated a staggering $11bn.

Not all online pharmacies are illegal; many adhere to the regulations for the selling and distribution of prescription drugs. However, a random sampling of 10,000 online pharmacies by the FDA found 97% of them to be illegal or not conforming to the regulations. Despite this, it was also found that one in four American consumers buy their prescription medicines online. For the consumer, differentiating between the illegal and legal online pharmacies can be difficult due to a lack of awareness about the issue, and the similarity in appearance between legal and illegal outlets.

While the illegal or black market trade of pharmaceuticals is not a new issue, the presence of illegal online pharmacies has grown in recent years. Part of this growth is due to increased awareness and visibility; as illegal pharmacies have moved onto the internet, they are much easier for consumers to find and access. It has been estimated that there are approximately 40,000 illegal online pharmacies. The fact that there is such a large number of these organisations is due to a combination of two major factors.

First, at $560bn, the prescription drug market dwarfs other illicit drug markets many times over, offering hugely lucrative opportunities. One group reportedly made sales of £55m ($72.9m) over a 12–15 month period through their illegal online pharmacy.

Second, despite the fact that these pharmacies are illegal, the detection and prosecution of the organisations running these pharmacies is extremely difficult, with the Medicines and Healthcare products Regulatory Agency stating that it was completely impossible to control online pharmacies, due to the sheer number of them present on the internet. This has given rise to a perfect storm of high reward and low risk, which has fuelled the growth of illegal online pharmacies.

For more insight and data, visit the GlobalData Report Store.

Share this article

Go to article: Home | Trust In Big PharmaGo to article: EditorialGo to article: NSFGo to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: FreudenbergGo to article: The Pharma Industry BriefingGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: Humira: the highs and lows of the world’s most successful drug Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Gene therapy: talking smart solutions with Bluebird BioGo to article: Moehs Iberica Company InsightGo to article: Moehs Iberica SLGo to article: A research headache: improving the understanding of chronic migraine Go to article: SensitechGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Philanthropy in pharma: a look inside the ISPE FoundationGo to article: DelSiTechGo to article: Novel Oral Therapies Are An Unmet Need For Ulcerative ColitisGo to article: PhoenixGo to article: FDA removes key barrier to US biosimilar developmentGo to article: Nipro PharmaPackagingGo to article: Pfizer price hikes: do rare cancer drugs warrant higher prices?Go to article: AlpexGo to article: Head-to-head: competing for the most effective psoriasis drugGo to article: Mecmesin Company InsightGo to article: MecmesinGo to article: Takeda to seek label expansion for Ninlaro in multiple myelomaGo to article: Capsugel Company InsightGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Epilepsy: Zogenix’s ZX008 set for showdown with GW Pharma’s EpidiolexGo to article: EcocoolGo to article: Abiogen PharmaGo to article: Illegal online pharmacies: how endemic are they?Go to article: Global Freight Solutions LtdGo to article: The boom in medical cannabis research is set to continueGo to article: AtoZ-CRO GmbH Company InsightGo to article: AtoZ-CRO GmbHGo to article: Population boom will boost acute stroke market, particularly in ChinaGo to article: Pall BiotechGo to article: Cryo StoreGo to article: Watch Alibaba instead of Amazon in healthcareGo to article: WIKA - Disaster preventionGo to article: AstraZeneca’s Lynparza maintains lead in PARP inhibitor raceGo to article: G.F.Go to article: Erdmann Design SwitzerlandGo to article: CMV presents a serious concern in HIV+ personsGo to article: BEA TechnologiesGo to article: BaxterGo to article: bDMARD therapy: adherence in the first year is key to successGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: End the struggle: pathways to HEAL the opioid crisisGo to article: LaudaGo to article: AbbVie poised to overtake Gilead as hepatitis C leaderGo to article: ILC Dover IncGo to article: ViiV results show the importance of INIs to future HIV treatmentGo to article: PfanstiehlGo to article: Novartis acquires rights to atopic dermatitis candidate MOR106Go to article: Niconex Medical LtdGo to article: EventsGo to article: Next issue